Thus, recombinant therapeutic proteins can be classified as either natural analogs or those consisting of proteins or protein fusions that do not occur in nature. A *bona fide* example of recombinant proteins are the well known class of therapeutic antibodies and their derivatives. Canonical antibodies have already been discussed in a plethora of other books and reviews. *Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges*, edited by Stefan R. Schmidt, focuses rather on the lesser acclaimed but equally important class of bioactive proteins that are artificially generated by joining 2 or more genes by genetic engineering. These new designs have not only the potential to combine several therapeutic functions in one molecule, but can also be engineered to extend half-life, stability, mechanism of action or offer novel delivery routes. There are, however, intrinsic challenges that need to be overcome, such as immunogenicity that may occur due to the formation of novel epitopes at the junction between the fusion partners even if fully human proteins are connected. The advantages of this class of therapeutic proteins, and the intrinsic challenges and economic considerations of their development, are very well presented in this book.

The book has a total of 6 main parts: Introduction (I); Fusion proteins for half-life extension (IIA); Cytotoxic fusion proteins (IIB); Fusion proteins targeted to specific cells, organs and tissues (IIC); Novel concepts and scaffolds (IIIA); and Multifunctional antibodies (IIIB). In Part I, the editor **Stefan R. Schmidt** gives a broad introduction to the exciting field of fusion protein technologies, providing the historical background of the most important examples, their categories and fundamental challenges in design, engineering and prerequisites for manufacturing. He introduces the \"triple T paradigm\" to describe the 3 major functions of fusion proteins. The three "t" of this paradigm are "time" (t~1/2~ or half-life), "toxicity" and "targeting" (binding to another molecule specifically). He explains that antibodies naturally link all 3 functions in one molecule. The chapter closes with a market analysis and future perspectives, thereby already giving a flavor of the following chapters of this stimulating book.

**Mark Belsey** and **Giles Somers** expand into the dynamics of the fusion protein market with the most prominent sales and discussion of products such as etanercept (Enbrel®), abatacept (Orencia®), romiplostim (Nplate®), 2 glucagon-like peptide analogs dulaglutide (Trulicity^TM^) and albiglutide (Tanzeum^TM^), and aflibercept (EYLEA®). **Giles Somers** goes even deeper into the field with discussion of the various aspects of fusion proteins that determine the level of success, including factors such as route of administration, safety, efficacy, cost of goods and intellectual property. Examples are given for half-life extension by classical Fc- and or albumin fusions, which can be used to make targeted toxins, decoy receptors, and fused ligands. In the next chapter, **Xiaoying Chen**, **Jennica Zaro** and **Wei-Chiang Shen** present a very comprehensive overview of the highly important aspect of linker-design. The choices are manifold, starting from the classical flexible or rigid linkers, through in vivo cleavable linkers, up to the more complex ones that could substantially improve biological activity, expression levels and pharmacokinetics. The highly challenging aspect of immunogenicity is taken up by the **Vibha Jawa, Leslie Cousens** and **Anne S. De Groot** in the last chapter of Part I. The basics of therapeutic immunogenicity are outlined, as well as the most important tools for immunogenicity screening. The latter topic is very well summarized in tables and figures comprising the most important epitope prediction tools such as EpiScreen, Epibase, EpiMatrix, IEDB and other algorithms. Examples of the predicted *versus* observed immunogenicity for 20 human and chimeric antibodies are given, as well as strategies and recommendations for preclinical and clinical immunogenicity assessment strategies.

In Part IIA, **Stefan R. Schmidt** introduces the principals of fusion protein half-life extension, providing a good summary of the available technologies, highlighting certain strengths and weaknesses of the different approaches. The differential impact of certain strategies is well demonstrated for glucagon-like peptide 1 and exendin-4. The well-developed techniques of Fc and albumin fusions that exploit the FcRn recycling machinery are introduced and are covered in considerable detail in 4 subsequent chapters. **Baisong Mai, Susan Low, Snejana Krassova, Robert Peters, Glenn Pierce** and **Jennifer Dumont** describe monomeric Fc-fusions as an option to modify and potentially enhance the therapeutic effects of Fc-fusions. The increased bioavailability of Fc-monomers compared to Fc-dimers is demonstrated with examples, including EPO, IFN-β, IFN-α, factor VIII and factor IX. The advantages are not always found via the same mechanisms, and the authors shed light on the different reasons for which this approach is of interest.

Peptide therapeutics hold great promise for the generation of therapeutic agonists, but their successful entry to the market can be retarded by a multitude of factors. **Chichi Huang** and **Ronald Swanson** first present the numerous hurdles that peptides face, including the hostile environment of the human body, which is replete with peptidases and has a highly efficacious filtration system in the form of the kidneys that rapidly eliminate this therapeutic class. Techniques to improve peptide longevity and alternative half-life extension technologies are then discussed in some depth. Examples of peptide-Fc fusions approved for therapeutic use or in clinical testing, including NPlate® and Trulicity^TM^, with a welcome level of detail concerning the observed half-life of the compounds, complement the discussion. Advancements of this particular technology that are needed to improve tolerability, stability, activity and developability are also introduced.

The fusion concept is extended by **Aris Economides** and **Neil Stahl** to include Fc-receptor fusions, as exemplified by the anti-TNF drug Enbrel®, culminating with the multifaceted ligand trap format. The different approaches are shown to open the way to use heterogenous Fc fusions to target single or multiple targets in patient serum with high levels of efficacy and specificity. Clinical data in this domain is presented, although, at the time of writing, conclusive proof that this technology will displace conventional monoclonal antibodies is lacking.

The advantages of Fc fusions are numerous, but often come at the price of complex production and purification procedures. Compared with Fc-fusions, the highly abundant protein serum albumin possesses similarly long half-life characteristics, but has the advantage of being a well-characterized monomer that can be readily produced in yeast and mammalian cells. **Thomas Weimer, Hubert Metzne**r and **Stefan Schulte** introduce the breadth of compounds currently in early- and late-stage clinical development, including glucagon-like peptide-1 and EPO, revealing interesting comparisons to alternative fusion technologies. The theme of exploiting serum albumin indirectly through fusion of albumin-binding moieties to the therapeutic continues in the following chapter. Domain antibodies that bind albumin have been indentified, and demonstrate serum half-life similar to that of albumin itself. **Adam Walker, Grainne Dunlevy** and **Peter Topley** describe the application of albumin-binding domain antibodies, also known as AlbudAbs^TM^, as fusion partners for both antagonists and agonists. The small size and homogenous nature of this fusion partner makes them of particular interest. Perspectives for further innovation are introduced through the examples of albumin-binding peptides and small molecules, with both identified from library screening approaches.

A new concept for shortening the half-life of autoantibodies is outlined by **Dennis Keefe, Michael Heartlein** and **Serene Josiah**. Autoantibodies that block acetylcholine receptors can cause Myasthenia gravis, a severe autoimmune disease. SHG2210 is a fusion protein of the nicotinic acetylcholine receptor α and human transferrin. Antibodies binding to the fusion protein are guided to the lysosome for proteolytic destruction via transferrin receptor-mediated uptake.

Methods for the half-life extension of human growth hormone (GH) are described in 2 chapters. **Fuad Fares** discusses the details of glycoengineered hormones. These are created via fusion of the carboxy-terminal peptide (CTP) of the human chorionic gonadotropin, giving rise to O-glycosylation. Phase 1 clinical study results of CTP-modified GH (hGH-CTP) indicated fortnightly injection of this glycoprotein hormone might be sufficient to replace the daily injections required using conventional GH. Other CTP-fused hormones are in clinical and preclinical development. **Sarbendra Pradhananga**, **Ian R. Wilkinson**, **Eric Ferrandis**, **Peter J. Artymiuk**, **Jon R. Sayers** and **Richard J. Ross** describe the therapeutic application of the growth hormone receptor (GHR) fused to its ligand (GH). This fusion protein has an unexpected agonistic activity and much longer half-life compared to the GH alone, permitting 3 to 4 weekly injections instead of daily, although dosing remains more frequent than for the alternative GH-CTP fusion proteins.

Elastin-like polypetides (ELPs) are composed of repetitive polypeptides with a high homology to the hydrophobic domain of elastin. The fusion of ELPs to therapeutic proteins, their expression in plants and their unique method of purification are recapitulated by **Doreen M. Floss**, **Udo Conrad**, **Stefan Rose-John** and **Jürgen Scheller**. The reversible conversion of ELPs from aggregate to soluble forms through a temperature-induced inverse phase transition that can be exploited both for nonchromatographic purification, as well as therapeutic purposes, is elegantly introduced.

Therapeutic cytokines have 2 inherent drawbacks: (1) short half-life, and (2) potentially severe side effects. Both can be addressed by fusing them to the latency-associated peptide of TGF-β and a cleavage site for metalloproteases. **Lisa Mullen**, **Gill Adams**, **Rewas Fatah**, **David Gould**, **Anne Rigby**, **Michelle Sclanders**, **Apostolos Koutsokeras**, **Gayatri Mittal**, **Sandrine Vessillier** and **Yuti Chernajovsky** discuss the advantages of this concept and how these fusion proteins can increase both the specificity of cytokines and their half-life.

Part IIB of the book delineates fusion proteins with cytotoxic activity. These fusion proteins are generally classified in 2 categories: 1) those that are active at the cell surface; or 2) those activated after internalization. Most fusion proteins that are active at the cell surface gain their cytotoxic effect by activating cells of the immune system, whereas those that include toxins and enzymes are designed be active inside the cell. After introducing these concepts, **Jung Hee Woo** and **Arthur Frankel** report details of classic immunotoxins derived from bacterial or plant toxins such as *Diphtheria* toxin, *Pseudomonas* exotoxin, gelonin and saporin. Typically such toxins are fused to antibodies, antibody fragments, growth factors, adhesion molecules or cytokines. Although classical immunotoxins have been in development for many years, their immunogenicity and side-effects in the clinic remain as major hurdles.

Interleukin (IL) 2 has strong anti-tumor activity, and it was the first cytokine approved to treat skin melanomas and cancer of the kidney. However, it causes major adverse events, which can be limited when the drug is infused intratumorally. Fusing cytokines, chemokines or co-stimulatory molecules like OX40L, CD137L and GITRL to an antibody can increase their tumor specificity. This approach is summarized by **Leslie A. Khawli**, **Peisheng Hu**, and **Alan L. Epstein** and compared to Fc fusion protein lacking the Fab domains. Surprisingly, not only antibody fusion proteins, but also Fc fusions induced significant tumor regression in immunocompetent mice. **Nikolai G. Rainov** and **Volkmar Heidecke** focus on therapies based on immunotoxins against gliomas. These include a permuted form of IL4 fused to a truncated form of the *Pseudomonas* exotoxin, TGF-α fused to the same toxin and a mutant form of the diphtheria toxin conjugated to human transferrin. These constructs have entered clinical trials, but major problems with uneven distribution of the drug in the brain and nonspecific toxicity remain to be solved. **Stefan Barth**, **Stefan Gattenlöhner** and **Mehmet Kemal Tur** report on immunokinases, fusion proteins of pro-apoptotic protein kinases and antibodies, antibody fragments or ligands. These constructs restore the normal apoptotic function of a tumor suppressor gene to a tumor cell, when a tumor specific antigen is targeted by the binding moiety. The technology is exemplified by the immunokinase fusion of the pro-apoptotic DAP kinase DAPK~2~ and the CD30 ligand. Another class of toxic fusion proteins named "immunoRNase" is discussed by **Wojciech Ardelt**. Several different ribonucleases have been chemically or genetically fused to binding moieties to target tumor cells. Among these, onconase, described as having strong cytostatic and cytotoxic activity against human cancer cells without a fusion partner, has entered Phase 3b clinical trials. Low expression rates of immunoRNases in classical expression systems remain a limiting factor to the exploitation of their therapeutic potential.

Instead of linking a toxin to an antibody or another binding moiety, they can be fused to enzymes that render a non-toxic prodrug into a cytotoxic drug. These therapeutic molecules are the basis of antibody-directed enzyme prodrug therapy (ADEPT). Insights into this therapy are provided by **Surinder K. Sharma**. ADEPT is designed to increase the specificity of chemotherapy. Compared to antibody toxin fusions, ADEPT can amplify the toxic effect of the fusion protein, and might have a stronger cytotoxic effect on bystander cells. The specific effect can only be achieved when the antibody-enzyme fusion remains on the surface of the tumor, but is cleared from the blood stream. Therefore, antigens that are rapidly internalized are not suitable. An antibody targeting the carcinoembryonic antigen fused to carboxypeptidase G2 in combination with the bis-iodo phenol mustard prodrug was evaluated in clinical trials.

Another alternative to fusing a toxin to an antibody is the fusion of an antibody fragment to a bacterial superantigen. The concept is termed tumor-targeted superantigens (TTS), and it is outlined by **Gunnar Hedlund**, **Göran Forsberg**, **Thore Nederman**, **Anette Sundstedt**, **Leif Dahlberg**, **Mikael Tiensuu** and **Mats Nilsson**. Through binding to MHC class II molecules and interaction with T cells receptors, bacterial superantigens are among the most efficient inducers of inflammatory cytokines and T cell-mediated cytotoxicity. When fused to a tumor targeting Fab fragment, superantigens can direct T cells against the tumor cells. The clinically most advanced TTS is naptumomab estafenatox, which showed a favorable safety profile and is currently in pivotal Phase 2/3 trials.

Part IIC of the book focuses on strategies for targeting fusion proteins. In the first chapter of this section **Stefan R. Schmidt** deliberates strategies to target the brain a typically intractable organ due to its separation from the circulation by the blood-brain barrier (BBB). Most of these rely on receptor-mediated transcytosis using ligands of, or antibodies against, the transferrin or insulin receptor. Other examples of organ-targeting fusion proteins, including the EPO-Fc fusion and a scFv targeting the secretory component fused to α1-antitrypsin for pulmonary delivery are described. As extensions to this approach, fusion protein delivery to the lysosome in enzyme replacement therapy or escape from the endosome to enter the cytoplasm are also addressed. The last part of this chapter discusses the first approaches for the oral delivery of fusion proteins.

The topic of cell-penetrating peptides (CPPs) or protein transduction domains (PTDs) is further discussed by **Andrés Muñoz-Alarcón**, **Henrik Helmfors**, **Kristin Karlsson** and **Ülo Langel**. CPPs either alone or as a transduction domain in a fusion protein have the ability to cross the plasma membrane of any cell independent of the cell type or its receptors. A large number of these have entered preclinical and clinical development. These include a tumor suppressor protein p53 fusion protein for anti-cancer treatment and the transcription factor Foxp3 fused to a CPP. Foxp3 is expressed in regulatory T cells and is important for immunological self-tolerance. Other preclinical examples of CPP fusion proteins include anti-apoptotic proteins like BH4 and Bxl-xl. The Nogo-A extracellular peptide residues 1--40 (NEP1--40) fused to the CPP of the HIV TAT protein is an example of a molecule that not only enters living cells, but also crosses the BBB to promote neurite outgrowth in the brain. These and other examples given by the authors stress the therapeutic potential of CPP fusion proteins.

A completely different concept for delivering biopharmaceuticals to a target cell is reported by **Jiajing Wang**, **Zhenzhong Ma**, and **Jeffrey A. Loeb**. Proteoglycans, a major component of extracellular matrices, are composed of glycosaminoglycans (GAGs) that are covalently attached to the core proteins. Among these, heparan sulfates are very specific for certain cell types in a specific organ. Fusion proteins that include a heparin-binding domain (HBD) can make use of this specificity. Examples given in this chapter include the fusion of the HBD of heparin-binding EGF-like growth factor to the insulin-like growth factor-1 (IGF-1) to increase the specificity of the growth factor and minimize systemic effects.

Hypophosphatasia is a metabolic bone disease that is caused by mutations of the tissue-nonspecific alkaline phosphatase (TNSALP). **José Luis Millán** presents the concept of ENB-0040, a bone targeted enzyme replacement therapy to treat hypophosphatasia. ENB-0040 is a fusion protein of TNSALP, the Fc domains of a human IgG1 and a bone-targeting peptide. First attempts of an enzyme replacement therapy using TNSALP alone indicated that the enzyme needs to be targeted to the skeleton to be effective. Preliminary data of first clinical trials indicated a high efficacy of ENB-0040 in children with hypophosphatasia.

**Jessica Fioravanti**, **Jesús Prieto**, and **Pedro Berraondo** describe the therapeutic potential of a fusion protein containing IFN-α and lipoprotein A-I. IFN-α is a secreted cytokine with strong anti-viral activity. Apolipoprotein A-I promotes the transport of high density lipoprotein from tissues to the liver and the efflux of cholesterol. Therefore, it is an appropriate fusion partner to target the liver with therapeutic proteins like IFN-α. This fusion protein has a much longer half-life than unmodified IFN-α and preserves its anti-viral activity. Surprisingly the fusion protein has a stronger immunoregulatory effect than IFN- α alone, but less hematological toxicity.

In Part III, the first 5 chapters describe novel concepts and novel scaffolds and the last 6 chapters are devoted to multifunctional antibodies. In the first chapter of this part, **Mark L. Tykocinski** outlines the concept of signal converter proteins. These recombinant proteins modulate the cell signals that are exchanged upon cell-cell contact. Examples given in this chapter include the fusion protein CTLA-4·FasL and CD40·FasL.

The novel concept of using soluble T-cell antigen receptor fusion protein as therapeutic molecules are presented in chapters by **Peter R. Rhode** and by **Nikolai M. Lissin, Namir J. Hassan** and **Bent K. Jakobsen**. Several technical difficulties had to be overcome to employ T-cell antigen receptors (TCR) for therapeutic and diagnostic purposes. These include the low expression levels of soluble TCRs and the instability of the paring of the 2 chains. One way to overcome these problems is to express TCRs as 3 domain single-chains by fusing the variable domain of the α chain with a linker peptide to the variable and the constant domain of the β-chain (scTCR). An alternative to this approach is the introduction of an interchain disulfide bridge (mTCR). A major advantage of recombinant TCRs is that they can specifically target intracellular antigens that are presented on the peptide antigen/MHC complex, and which are otherwise not accessible on the cell surface. For potency, these molecules need to be fused or conjugated to a moiety with a strong therapeutic effect. The most advanced therapeutically active scTCR fusion protein is ALT-801, a soluble single-chain TCR against p53 (aa264--272)/HLA-A\*0201 complex fused to IL2. The most advanced mTCR is a TCR·scFv fusion protein in which the TCR targets gp100 and the scFv binds to CD3.

The characteristics and development of amediplase are explored by **Stefano Evangelista** and **Stefano Manzini**. Amediplase is a recombinant plasminogen activator for the treatment of acute myocardial infarction. This fusion protein contains the kringle 2 domains of tPA and protease domain of pro-urokinase plasminogen activator. An effective dose of 1.0 to 1.2 mg/kg was determined in Phase 2 trials. The incidence of adverse events was low and a prolonged half-life compared to other plasminogen activators was determined.

**H. Kaspar Binz** discusses the theoretical advantages of the novel scaffold called designed ankyrin repeat proteins (DARPins) over therapeutic antibodies and antibody fragments. One major advantage of this new scaffold is the absence of disulfide bonds and glycosylation sites. Therefore, DARPins can be expressed in the cytoplasm of *E. coli* and be produced without refolding at a very high rate. Different DARPins can be genetically fused to generate multispecific constructs without loss of the favorable characteristics of the monomeric protein.

In the last 8 chapters, progress in the development of multifuctional antibodies is outlined. **Patrick A. Baeuerle** and **Tobias Raum** introduce this subject by giving a detailed overview of bispecific antibodies. The many different formats of bispecific antibodies are categorized by the authors as IgG-like constructs, Fc-gamma fusion proteins, Fab fragment based constructs and constructs that are based on single-chain Fv or diabody fusion proteins. IgG-like bispecific antibodies are either asymmetric or symmetric. Asymmetric bispecific antibodies bear the inherent problem of heavy and light chain mispairing. This problem has been solved by using a single light chain that matches with both heavy chains or by changing the VL-CL/VH-CH1 arrangement on one arm of the bispecific antibody. The naturally occurring Fab arm exchange of IgG4 can also be employed to generate asymmetric IgG-like bispecific antibodies. Recognition of 2 antigens by symmetric IgG-like bispecific antibodies can be generated by several techniques. The fusion of 2 different VHH domains to the constant domains of an IgG falls into this category. A defined cross-reactivity of an otherwise structurally unchanged IgG or an engineered CH3 domain that binds specifically to an antigen are 2 other examples. Chemical cross-linking of 2 antibodies or a bispecific ligand are 2 other techniques for the generation of symmetric IgG-like bispecific antibodies that have entered clinical development. A large number of bispecifics represent fusion proteins whereby at least one fusion partner is an antibody fragment such as an Fab or scFv. These can either be fused to the Fc domains of an IgG for increased half-life and effector function or to another antibody fragment. The authors discuss the main aspects for the selection of a bispecific antibody format in the context of its half-life, desired effector function, determination of adverse events and tissue penetration.

One bispecific antibody format based on diabodies, dual affinity retargeting technology (DART), is explored by **Syd Johnson**, **Bhaswati Barat**, **Hua W. Li**, **Ralph F. Alderson**, **Paul A. Moore** and **Ezio Bonvini**. In this format, the association of VH-VL is stabilized by incorporating a disulfide bond between the C-termini of the VH domains. An example of a DART protein for the treatment of autoimmune diseases based on the cross-linking of an inhibitory and an activating receptor on the same cell is given. This DART down-regulates the activation of B cells by cross-linking CD32B and CD79A. Other DARTs that recruit immune effector cells to tumors are outlined in this chapter. **Alec W. Gross**, **Jessica P. Dawson**, **Marco Muda**, **Christie Kelton**, **Sean D. McKenna**, and **Björn Hock** present the generation of an asymmetric IgG-like bispecific format based on their strand-exchange engineered domain (SEED) platform. In the SEED platform, 2 different CH3 domains have been engineered by combining sequences of the human IgG and IgA CH3 domains. The SEED scaffold has similar characteristics as the wild type IgG with regards to pH stability and effector activities, e.g., antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC).

The concept of CovX-Bodies is reviewed by **Abhijit Bhat**, **Olivier Laurent** and **Rodney Lappe**. CovX-Bodies contain a humanized antibody, an azetidinone (AZD) linker and a payload. The payload is conjugated specifically to a lysine residue in the VH domain of the CVX-2000 antibody by its inherent catalytic activity mimicking class I aldolases. Unlike other therapeutic antibody conjugates, in CovX-Bodies the antibody serves as a carrier protein to increase half-life and bivalency. The therapeutic effect is determined by the payload. The "Fc molecule with antigen-binding properties" (Fcab) scaffold concept is described by **Maximilian Woisetschläger**, **Florian Rüker**, **Geert C. Mudde**, **Gordana Wozniak-Knopp**, **Anton Bauer** and **Gottfried Himmler**. Fcab are based on the engineering of the non-complementarity-determining region loops in the CH3 domain. Binding of Fc-receptors and C1q, as well as a long half-life, are retained in Fcab molecules. The Fcab scaffold can replace the wild-type CH3 in a modular fashion to create bispecific or multivalent antibodies. An Fcab scaffold grafted on rituximab and trastuzumab showed similar ADCC and CDC activity as the corresponding parental antibodies. In the last chapter of the book, **Edmund A. Rossi**, **David M. Goldenberg** and **Chien-Hsing Chang** present "dock-and-lock" (DNL), a modular platform technology for generating stably tethered structures of defined compositions with multiple functionalities or binding specificities. The basis of this technology is the dimerization-docking domain of protein kinase A (PKA; cyclic AMP--dependent protein kinase) and the anchor domain (AD2) of the A-kinase anchoring protein. Major advantages of DNL include the modularity of the building blocks. Building blocks of very different nature can be produced in different expression systems and conjugated after expression or synthesis of each building block.

In conclusion, *Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges* provides a broad and up-to-date overview of the therapeutic fusion protein field. The authors' contributions are high quality, but there some cases of an "inherent" redundancy and attention to details that might appeal only to the expert reader. However, this is very well compensated by the editor, Stefan R. Schmidt, who gives several excellent introductions and overviews along the different parts of the book. The only weakness of the book are some poorly illustrated figures, in contrast to the many very informative tables. Overall, this book is a "*bona fide*" companion for newcomers, as well as for experts in the pharmaceutical industry, in biotechnology or universities with affiliations to industry and medicine.
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